SUDA Acquires Novel Oro-Mucosal Anti-Cancer Agent
Filed with ASX · · 2 pages · English
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- SUDA Publishes Amended Shareholder Newsletter
- SUDA Achieves ISO Accreditation
- Strong Revenue Growth for SUDA Subsidiary
- SUDA Enters Licence Agreement With Teva
- SUDA Signs Term Sheet To Acquire Anti-Cancer Agent
Later from Arovella Therapeutics
- SUDAs Licensee Submits Marketing Application
- SUDA Completes Acquisition Of Anti-Cancer Agent
- New Analyst Report
- Divestment Of Non-Core Subsidiary
- SUDA Completes Divestment of Subsidiary
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics